DETECT III – A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

NCT01619111
Breast cancer type: HR+ & HER2-negative
Recruitment status: Recruiting
Phase 3
Interventions: Drug: standard chemo- or endocrine therapy|Drug: standard chemo- or endocrine therapy + Lapatinib
Drug category:

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of metastases:
Additional Notes:
Exclusions: Male patients
https://ClinicalTrials.gov/show/NCT01619111

Comments are closed.

Up ↑